FindMyKOL
Clinical trialNCT01076231CompletedPhase 1/2Interventional

Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

NCT01076231 is a phase 1/2 interventional trial sponsored by Abramson Cancer Center at Penn Medicine. As of 21 Nov 2026, it is completed. It studies Cisplatin and Etoposide in Stage IIIA Non-small Cell Lung Cancer. The registry lists an enrollment of 34 participants at 1 site in 1 country. The registry lists a start date of 31 Jan 2010 and a primary completion date of 31 Dec 2016.

SponsorAbramson Cancer Center at Penn Medicine →Enrollment34Stage IIIA Non-small Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01076231
FieldValue
Registry IDNCT01076231
StatusCompleted
PhasePhase 1/2
Study typeInterventional trial
Lead sponsorAbramson Cancer Center at Penn Medicine
Enrollment34
Registered sites1
Countries1
ConditionsStage IIIA Non-small Cell Lung Cancer
DrugsCisplatin and Etoposide
Start31 Jan 2010
Primary completion31 Dec 2016
Study completion24 May 2018
Last update posted17 May 2021

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Specialized radiation therapy, such as proton beam radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue in patients with non-small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving proton beam radiation therapy together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of proton beam radiation therapy when given together with cisplatin and etoposide and to see how well it works in treating patients with stage III non-small cell lung cancer that can be removed by surgery.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Pennsylvania, United States1 site
  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvania: 1 sitePA1New JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT01076231

Each answer restates registry values shown on this page.

What is NCT01076231?

NCT01076231 is a phase 1/2 interventional trial sponsored by Abramson Cancer Center at Penn Medicine. It studies Cisplatin and Etoposide in Stage IIIA Non-small Cell Lung Cancer.

Who leads NCT01076231?

The registry names Jacob Shabason, MD (principal investigator, Abramson Cancer Center at Penn Medicine) as the overall official.

Where does NCT01076231 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT01076231 study?

The registered drug and biological interventions are Cisplatin and Etoposide.

When did NCT01076231 end?

The registry lists a primary completion date of 31 Dec 2016 and a study completion date of 24 May 2018. The sponsor last updated the record on 17 May 2021.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.